Clinical trial
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or…
NCT00072267 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00072267 |
|---|---|
| Title | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| Official title | A Phase II Study of UCN-01 in Combination With Topotecan in Patients With Advanced Ovarian Cancer |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | 7-hydroxystaurosporine, topotecan hydrochloride |
| Start date | Jan 1, 2004 |
| Primary completion | Apr 1, 2005 |
| First posted | Nov 6, 2003 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: